Medical Condition News

RSS

J-LANCELOT trial finds E5555 may reduce MACE without increasing serious bleeding events

Aspirin and thienopyridine antiplatelet therapy (such as clopidogrel) are standard care in the treatment of acute coronary syndrome (ACS) and even in stable coronary artery disease (CAD) after coronary intervention with stent. However, effective antiplatelet agents are needed which do not increase the risk of bleeding.

31 Aug 2010

Cell Therapy Foundation analysis calls for funding in medical research

Some of the most promising medical research conducted to treat diseases of the brain, heart, and circulatory system is moving too slowly to help millions of patients, according to the Cell Therapy Foundation, which advocates the use of adult stem cells to dramatically impact and improve the condition of patients who suffer from a variety of conditions.

31 Aug 2010

Antithrombotic therapy increases bleeding risk in CAD patients: Research

Antithrombotic therapy using antiplatelet and anticoagulant agents is the cornerstone of treatment for acute and chronic coronary artery disease (CAD), yet it is also associated with an increased risk of bleeding. It is paradoxical that elderly patients, the most likely population to develop CAD, are those that suffer most from bleeding complications.

31 Aug 2010

Tapentadol ER improves average intensity of chronic osteoarthritis knee pain: Study

Phase 3 safety and efficacy data comparing tapentadol extended release (ER) tablets, an investigational pain medication, to placebo in patients with moderate to severe chronic osteoarthritis knee pain have been published by Clinical Drug Investigation.

31 Aug 2010

Roche's MabThera continues to dwarf recently launched monoclonal antibodies: Report

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, 41 percent of surveyed European hematologist-oncologists say that the favorable efficacy profile of Roche's MabThera (rituximab) is the most significant driver of their use of this brand, while 26 percent say MabThera's favorable risk-benefit profile is the most significant driver.

31 Aug 2010

FDA grants Priority Review status to Alimera Sciences' Iluvien for diabetic macular edema

Alimera Sciences, Inc.,, a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that the Company's New Drug Application (NDA) for Iluvien® (fluocinolone acetonide intravitreal insert) has been accepted for filing and granted Priority Review status by the U.S. Food and Drug Administration (FDA).

31 Aug 2010

VA's liabilities grow as agency expands list of diseases linked to Agent Orange

Politico looks at a new fight brewing over Agent Orange and how it affects programs for Vietnam Veterans. "It's a world turned upside-down from decades ago when returning soldiers had to fight to get attention for deadly lymphomas linked to the herbicide. Now the frailties of men in their 60s — prostate cancer, diabetes, heart disease — lead the list of qualified Agent Orange disabilities, and the result has been an explosion in claims — and the government's liability.

31 Aug 2010

FDA extends Prescription Drug User Fee Act date for ezogabine

GlaxoSmithKline and Valeant Pharmaceuticals International announced today the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for ezogabine to 30 November 2010.

31 Aug 2010

Intendis granted rights to KYTHERA's ATX-101 candidate for minimally-invasive fat reduction outside US, Canada

KYTHERA Biopharmaceuticals, Inc. and Intendis, Bayer HealthCare's dermatology business, today announced that they have entered into a licensing agreement granting Intendis rights to KYTHERA's lead product candidate, ATX-101, outside of the US and Canada. ATX-101, a first-in-class investigational drug, is currently in clinical development for the reduction of localized fat under the chin (submental fat).

31 Aug 2010

$Heparin enoxaparin may provide better outcomes than unfractionated heparin$

Heparin enoxaparin may provide better outcomes than unfractionated heparin

Results from ATOLL, a phase 3 randomised trial comparing two anticoagulants in primary PCI for ST elevation MI, show that the low molecular weight heparin enoxaparin may provide better outcomes in such cases than the traditionally used unfractionated heparin.

30 Aug 2010

Phase 2 INNOVATE PCI trial results for elinogrel presented

Phase 2 trial results for elinogrel, a novel antiplatelet agent available in both intravenous and oral formulations, were presented here today.

30 Aug 2010

Reactivation of CDX2 gene may halt progression of colon cancer

The intestines have to work properly if we are to benefit from the food we eat. Digestive juices must be secreted, the food broken down into smaller components and then transported through the gut wall and onwards to muscles and organs. The lining of the gut is coated in epithelial cells, a specialised layer that produces mucous and hormones while keeping dangerous bacteria and toxins at bay. Close contact with pathogenic microbes and toxins means that the epithelial cells may mutate to form cancer.

30 Aug 2010

BayCare Behavioral Health announces opening of Morton Plant North Bay Hospital Recovery Center in Lutz

As part of its continued commitment to meet the mental health needs of the Tampa Bay community, BayCare Behavioral Health has opened the Morton Plant North Bay Hospital Recovery Center in Lutz.

30 Aug 2010

Canada hosts 13th World Congress On Pain

The Canadian Pain Society (CPS) eagerly welcomes leading pain experts from across Canada and around the globe to the 13th World Congress on Pain in Montreal, Quebec, from August 29 to September 2. Hosted by the International Association for the Study of Pain (IASP), more than 6,000 pain professionals will gather to share their thoughts, research and best treatment practices concerning this throbbing public health issue.

30 Aug 2010

Smoked cannabis relieves chronic neuropathic pain

The medicinal use of cannabis has been debated by clinicians, researchers, legislators and the public at large for many years as an alternative to standard pharmaceutical treatments for pain, which may not always be effective and may have unwanted side effects. A new study by McGill University Health Centre (MUHC) and McGill University researchers provides evidence that cannabis may offer relief to patients suffering from chronic neuropathic pain.

30 Aug 2010

BioMarin's BMN-701 receives FDA orphan drug designation for treatment of Pompe disease

BioMarin Pharmaceutical Inc. announced today that it has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for BMN-701, a novel fusion of insulin-like growth factor 2 and alpha glucosidase (IGF2-GAA) in development for the treatment of Pompe disease. An investigational new drug application (IND) for BMN-701 has been submitted, investigational material has been manufactured and a Phase I/II study is expected to start in the first quarter of 2011.

30 Aug 2010

BDSI's Phase 2 study results of BEMA Buprenorphine selected for presentation at Pain Week 2010

BioDelivery Sciences International, Inc. announced today that its abstract showing the results of a Phase 2 clinical study of BEMA Buprenorphine in the treatment of pain has been selected for oral presentation at Pain Week 2010, a national conference educating frontline clinicians who are faced with treating patients with pain. The presentation will take place on Friday, September 10, as part of the 7:00 - 9:00 AM podium presentation session.

30 Aug 2010

Positron to host special ASNC 2010 symposium focusing on cardiac PET

Positron Corporation is pleased to announce K. Lance Gould M.D. as the keynote speaker for their upcoming cardiac PET symposium, held at the American Society of Nuclear Cardiology annual meeting, September 23-26 in Philadelphia, PA.

30 Aug 2010

Patients with atherothrombosis are at increased risk of ischemic events: Study

Clinical descriptors can assist clinicians in identifying patients with various stages of atherothrombosis (abnormal fatty deposits in an artery) who are at high-risk of future cardiovascular events, according to a study that will appear in the September 22 issue of JAMA. The study is being released early online to coincide with its presentation at the European Society of Cardiology meeting in Stockholm.

30 Aug 2010

Royal Philips Electronics launches new iE33 xMATRIX cardiac ultrasound system

Royal Philips Electronics today announced the enhanced iE33 xMATRIX cardiac ultrasound system featuring a new ergonomic solution for more efficient adult echocardiograms, the X5-1 transducer. With this enhanced technology, Philips continues its tradition of simplified, patient-focused healthcare solutions by providing a more complete imaging solution.

From Philips Healthcare 30 Aug 2010

Medical Condition News

J-LANCELOT trial finds E5555 may reduce MACE without increasing serious bleeding events

Cell Therapy Foundation analysis calls for funding in medical research

Antithrombotic therapy increases bleeding risk in CAD patients: Research

Tapentadol ER improves average intensity of chronic osteoarthritis knee pain: Study

Roche's MabThera continues to dwarf recently launched monoclonal antibodies: Report

FDA grants Priority Review status to Alimera Sciences' Iluvien for diabetic macular edema

VA's liabilities grow as agency expands list of diseases linked to Agent Orange

FDA extends Prescription Drug User Fee Act date for ezogabine

Intendis granted rights to KYTHERA's ATX-101 candidate for minimally-invasive fat reduction outside US, Canada

Heparin enoxaparin may provide better outcomes than unfractionated heparin

Phase 2 INNOVATE PCI trial results for elinogrel presented

Reactivation of CDX2 gene may halt progression of colon cancer

BayCare Behavioral Health announces opening of Morton Plant North Bay Hospital Recovery Center in Lutz

Canada hosts 13th World Congress On Pain

Smoked cannabis relieves chronic neuropathic pain

BioMarin's BMN-701 receives FDA orphan drug designation for treatment of Pompe disease

BDSI's Phase 2 study results of BEMA Buprenorphine selected for presentation at Pain Week 2010

Positron to host special ASNC 2010 symposium focusing on cardiac PET

Patients with atherothrombosis are at increased risk of ischemic events: Study

Royal Philips Electronics launches new iE33 xMATRIX cardiac ultrasound system

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Latest News